- All Aspects of General Corporate And Transactional Law
- Large Complex Vendor Relationships, In Regulated Industries
- Private Equity Financing Transactions
- Life Sciences, Medical Device, Biotech and Health Care Law and Finance
- Securities Law/Structuring/Compliance
- Securities Aspects of Syndicated Real Estate Transactions
- Handling National Clinical Trials For FDA Approvals
- Buy-Sell; In- and Out-Licensing Transactions
Mr. Fitzsimmons has over 30 years of broad transactional experience counseling both public and private companies – across a wide array of industries with an emphasis in the highly regulated industry space. He has negotiated and closed almost every sort of relationship and agreement any company with engineering or sciences in its background might find itself in need of.
His experience includes 17 years as senior counsel at a Fortune 200 engineering/sciences company, and chief counsel of its financing subsidiary – as its lead transactional and financial lawyer. He has spent the last several years in private practice – at boutique, mid-sized and large international law firms, representing all types of corporate entities.
He also has an extensive transactional background in real estate syndication, securities and finance, general corporate, commercial, M&A and science US regulatory matters. He handles negotiations and documentation for middle market corporate transactions of all types, including angel and later round financings, private placements, spin-offs, licensing, borrowing transactions, acquisitions, divestitures and recapitalizations as well as private equity and private wealth involvements – in growth stage companies.
Patrick also advises various boards of directors on general corporate and securities matters, including on Dodd-Frank and Sarbanes-Oxley, as well as general advice in a wide array of transactions, start-up companies, structuring private company acquisitions, initial capital structures, private equity and mezzanine investments. He also counsels medical doctors as clients acting as principal investigators in new drug and device trials, for FDA submission.